HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.

 

These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.

 

In this episode of HOPA Now, Dr. Shrina Patel covers dosage recommendations for ovarian cancer patients and the importance of molecular testing in order to provide treatment and maintenance recommendations and highlights the critical role of pharmacists in ensuring adherence to drug recommendations. She also offers an overview of drug treatments based on various inclusions and exceptions, addresses specific patient treatments, and covers radiation and management of varying acute and chronic toxicities.

 

In this episode, you will learn:

 

Gynecologic Malignancies: Top 10 Clinical Pearls

• Chemotherapy and dosage recommendations based on different ovarian cancer stages
• The importance of molecular testing for patients in order to provide treatment and maintenance recommendations
• The role of pharmacists in ensuring adherence to oral PARP inhibitors
• How and why the pharmacist needs to define a patient as platinum-resistant, sensitive, or refractory
• Recommended drugs for patients with recurrent or metastatic cervical cancer
• An overview of bone metastases and recommended drugs for proper treatment
• Radiation and management of its associated acute and chronic toxicities
• Hypertension and handling agent limiting bevacizumab treatments
• Inclusions and exceptions to treating patients with pembrolizumab and lenvatinib
• Recommendations for patients with uterine serous carcinoma

 

Mentioned in This Episode:

HOPA

 

Quotes:

 

“There are no randomized data supporting the use of this regimen in patients with stage 2 disease.” — Dr. Shrina Patel

 

“Oral chemotherapy has revolutionized oncology, yet with great achievements come challenges.” — Dr. Shrina Patel

 

“Radiation — with or without chemotherapy — is associated with acute and chronic toxicities.” — Dr. Shrina Patel